Business
Oncimmune and Scancell Present Autoantibodies Data
Oncimmune and Scancell Present Autoantibodies Data.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 0917P Scancell Holdings Plc 29 August 2017 \n\n 29 August 2017\n \n \nOncimmune and Scancell Present Data on use of Autoantibodies in Predicting Response to SCIB1 Immunotherapy\n \nEarlyCDT® demonstrates potential to predict disease recurrence\n \nNottingham, UK - 29 August 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, and Scancell Holdings plc, ('Scancell') the developer of novel immunotherapies for the treatment of cancer, today announce the presentation of data on the use of Oncimmune's autoantibody technology to successfully predict disease recurrence in subjects undergoing SCIB1 immunotherapy for malignant melanoma. The data will be presented at the Cambridge Healthtech Institute (CHI) Immuno-Oncology Summit 2017 on August 29th 2017.\n \nThe collaborative study, which also included a team at the University of Nottingham, developed a method using a panel of seven tumour associated autoantibodies to predict disease recurrence in patients with resected Stage III/IV melanoma treated with Scancell's SCIB1 immunotherapy. Whilst Phase I/II trials with SCIB1 have been highly encouraging, this additional information potentially enables the identification of patients prior to commencement of therapy who are most likely to respond to treatment in future clinical trials with SCIB1. \n \nGeoffrey Hamilton-Fairley, Chief Executive Officer, commented: \"This is the first of a number of companion diagnostics programmes we are undertaking, having shown with internal data that by usi...